Diabetes patients on GLP-1 treatments, like Ozempic, have a lower risk of 10 obesity-related cancers, per a study in JAMA Network Open.
Diabetes patients taking GLP-1 treatments, including Ozempic, have a lower risk of developing 10 types of obesity-related cancers compared to those taking insulin and other diabetes drugs, according to a study published in JAMA Network Open. Researchers analyzed medical records of 1.6 million type 2 diabetes patients, finding that patients on GLP-1 drugs had a significantly lower risk of developing cancers such as kidney, pancreatic, esophageal, ovarian, liver, and colorectal cancer.
July 05, 2024
40 Articles